Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120M
-
Number of holders
-
14
-
Total 13F shares, excl. options
-
5.22M
-
Shares change
-
-412K
-
Total reported value, excl. options
-
$33.3M
-
Value change
-
-$4.35M
-
Put/Call ratio
-
0.07
-
Number of buys
-
8
-
Number of sells
-
-21
-
Price
-
$6.38
Significant Holders of Avidity Biosciences, Inc. - Common Stock (RNA) as of Q3 2023
38 filings reported holding RNA - Avidity Biosciences, Inc. - Common Stock as of Q3 2023.
Avidity Biosciences, Inc. - Common Stock (RNA) has 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.22M shares
of 120M outstanding shares and own 4.35% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (4.01M shares), GOLDMAN SACHS GROUP INC (476K shares), CITADEL ADVISORS LLC (230K shares), CITIGROUP INC (143K shares), DEUTSCHE BANK AG\ (135K shares), Walleye Capital LLC (123K shares), Jump Financial, LLC (111K shares), Voya Investment Management LLC (52.8K shares), MetLife Investment Management, LLC (37.3K shares), and Tudor Investment Corp Et Al (35.2K shares).
This table shows the top 14 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.